Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RESTORE-IMI 2: IMI/REL vs PIP/TAZ in HABP/VABP
NCT03583333Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2018
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 3 trial of relebactam in hospital-acquired bacterial pneumonia (HAP), ventilator-associated pneumonia (VAP), sponsored by Merck & Co.. Started Sep 2018; status: completed.
02
Drugs
relebactam
03
Conditions
hospital-acquired bacterial pneumonia (HAP)ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03583333.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583333.